Literature DB >> 18625766

Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Jan Paeshuyse1, Inge Vliegen, Lotte Coelmont, Pieter Leyssen, Oriana Tabarrini, Piet Herdewijn, Harald Mittendorfer, Johnny Easmon, Violetta Cecchetti, Ralf Bartenschlager, Gerhard Puerstinger, Johan Neyts.   

Abstract

We report here a comparative study of the anti-hepatitis C virus (HCV) activities of selected (i) nucleoside polymerase, (ii) nonnucleoside polymerase, (iii) alpha,gamma-diketo acid polymerase, (iv) NS3 protease, and (v) helicase inhibitors, as well as (vi) cyclophilin binding molecules and (vii) alpha 2b interferon in four different HCV genotype 1b replicon systems.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18625766      PMCID： PMC2533444          DOI： 10.1128/AAC.01534-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Jeremy Clark; Laurent Hollecker; Stefania Lostia; Tammy Nachman; Jason Grier; Matthew A Bennett; Meng-Yu Xie; Raymond F Schinazi; John D Morrey; Justin L Julander; Phillip A Furman; Michael J Otto
Journal:  Antivir Chem Chemother       Date:  2006

2.  SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.

Authors:  Christoph Sarrazin; Regine Rouzier; Frank Wagner; Nicole Forestier; Dominique Larrey; Samir K Gupta; Musaddeq Hussain; Amrik Shah; David Cutler; Jenny Zhang; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

3.  Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.

Authors:  Hendrik W Reesink; Stefan Zeuzem; Christine J Weegink; Nicole Forestier; Andre van Vliet; Jeroen van de Wetering de Rooij; Lindsay McNair; Susan Purdy; Robert Kauffman; John Alam; Peter L M Jansen
Journal:  Gastroenterology       Date:  2006-10       Impact factor: 22.682

4.  In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.

Authors:  Sophie Le Pogam; Wen-Rong Jiang; Vincent Leveque; Sonal Rajyaguru; Han Ma; Hyunsoon Kang; Sharon Jiang; Margaret Singer; Samir Ali; Klaus Klumpp; Dave Smith; Julian Symons; Nick Cammack; Isabel Nájera
Journal:  Virology       Date:  2006-05-19       Impact factor: 3.616

5.  Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

Authors:  Nicole Forestier; Hendrik W Reesink; Christine J Weegink; Lindsay McNair; Tara L Kieffer; Hui-May Chu; Susan Purdy; Peter L M Jansen; Stefan Zeuzem
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

6.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors:  Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

7.  Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.

Authors:  Frederik Pauwels; Wendy Mostmans; Ludo M M Quirynen; Liesbet van der Helm; Carlo W Boutton; Anne-Stéphanie Rueff; Erna Cleiren; Pierre Raboisson; Dominique Surleraux; Origène Nyanguile; Kenneth A Simmen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 8.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

9.  Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.

Authors:  Sophie Le Pogam; Hyunsoon Kang; Seth F Harris; Vincent Leveque; Anthony M Giannetti; Samir Ali; Wen-Rong Jiang; Sonal Rajyaguru; Gisele Tavares; Connie Oshiro; Than Hendricks; Klaus Klumpp; Julian Symons; Michelle F Browner; Nick Cammack; Isabel Nájera
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.

Authors:  Sophie Le Pogam; Amritha Seshaadri; Alan Kosaka; Sophie Chiu; Hyunsoon Kang; Steven Hu; Sonal Rajyaguru; Julian Symons; Nick Cammack; Isabel Nájera
Journal:  J Antimicrob Chemother       Date:  2008-03-13       Impact factor: 5.790
View more
  12 in total

1.  Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

Authors:  Kelin Li; Kevin J Frankowski; Craig A Belon; Ben Neuenswander; Jean Ndjomou; Alicia M Hanson; Matthew A Shanahan; Frank J Schoenen; Brian S J Blagg; Jeffrey Aubé; David N Frick
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities.

Authors:  David N Frick; Olya Ginzburg; Angela M I Lam
Journal:  Methods Mol Biol       Date:  2010

3.  Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Authors:  Matthew A Gregory; Michael Bobardt; Susan Obeid; Udayan Chatterji; Nigel J Coates; Teresa Foster; Philippe Gallay; Pieter Leyssen; Steven J Moss; Johan Neyts; Mohammad Nur-e-Alam; Jan Paeshuyse; Mahmood Piraee; Dipen Suthar; Tony Warneck; Ming-Qiang Zhang; Barrie Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

4.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

5.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

6.  Substrate recognition by norovirus polymerase: microsecond molecular dynamics study.

Authors:  Kamil Maláč; Ivan Barvík
Journal:  J Comput Aided Mol Des       Date:  2013-04-26       Impact factor: 3.686

7.  Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication.

Authors:  Andrea Magri; Alexander A Ozerov; Vera L Tunitskaya; Vladimir T Valuev-Elliston; Ahmed Wahid; Mario Pirisi; Peter Simmonds; Alexander V Ivanov; Mikhail S Novikov; Arvind H Patel
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

Review 8.  Benzotriazole: An overview on its versatile biological behavior.

Authors:  I Briguglio; S Piras; P Corona; E Gavini; M Nieddu; G Boatto; A Carta
Journal:  Eur J Med Chem       Date:  2014-09-30       Impact factor: 6.514

Review 9.  Hepatitis C virus NS3 inhibitors: current and future perspectives.

Authors:  Kazi Abdus Salam; Nobuyoshi Akimitsu
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

Review 10.  Inhibition of RNA Helicases of ssRNA(+) Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families.

Authors:  Irene Briguglio; Sandra Piras; Paola Corona; Antonio Carta
Journal:  Int J Med Chem       Date:  2010-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.